CD19
Showing 1 - 25 of 8,705
B-cell NHL, CLL Trial (CARCIK-CD19)
Not yet recruiting
- B-cell NHL
- CLL
- CARCIK-CD19
- (no location specified)
May 19, 2023
Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)
Not yet recruiting
- Solid Tumor, Adult
- CF33-CD19 IT
- +2 more
- (no location specified)
Sep 26, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 CAR-T cell infusion
- (no location specified)
Oct 24, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 Universal CAR-γδ T Cells
- (no location specified)
Oct 24, 2023
Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Non Hodgkin Lymphoma Trial (TMhuCART19-IL18)
Not yet recruiting
- Non Hodgkin Lymphoma
- TMhuCART19-IL18
- (no location specified)
Aug 2, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)
Recruiting
- SLE (Systemic Lupus)
- +4 more
- CD19 targeted CAR-T cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Sep 25, 2023
Acute Myeloid Leukemia Trial in Ramat Gan (CAR-T CD19)
Recruiting
- Acute Myeloid Leukemia
- CAR-T CD19
-
Ramat Gan, IsraelChaim Sheba Medical Center
Oct 30, 2022
Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))
Recruiting
- Systemic Lupus Erythematosus (SLE)
- anti-CD19 CAR NK cells (KN5501)
-
Shanghai, ChinaChanghai Hospital
Aug 25, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)
Not yet recruiting
- Hematopoietic Stem Cell Transplantation
- Hematologic Malignancy
- CliniMACS®
- (no location specified)
Oct 17, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)
Active, not recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Refractory
- Cyclophosphamide
- +4 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jan 3, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 17, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)
Recruiting
- Central Nervous System Lymphoma
- Human CD19-CD22 Targeted T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 9, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma Trial (CD19-UCART)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- Non Hodgkin Lymphoma
- CD19-UCART
- (no location specified)
Jan 25, 2023